Saeedeh Farajzadeh; Soodabeh Zandi; Mohammad Mehdi Hayatbaksh Abbasi; Fahimeh Gadari; Armita Shahesmaeili; Behrooz Vares; Golamreza Hosseinpour; Iman Shojaei Baghini
Volume 14, Issue 3 , 2011, , Pages 81-85
Abstract
Background: The association between coronary artery disease and androgenic alopecia has been demonstrated, but few studies have focused on the mechanism of this association. The aim of this study was to evaluate the lipid profile in male pattern alopecia.Methods: In this case control study, 45 male patients ...
Read More
Background: The association between coronary artery disease and androgenic alopecia has been demonstrated, but few studies have focused on the mechanism of this association. The aim of this study was to evaluate the lipid profile in male pattern alopecia.Methods: In this case control study, 45 male patients with androgenic alopecia who were aged from 20 to 50 years and 45 men with a normal hair status aged from 20 to 50 years were enrolled as the case and control groups, respectively. Lipid parameters including cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, lipoprotein (a), apolipoprotein A1, apolipoprotein B were measured in cases and controls.Results: A significant difference in serum lipoprotein (a) was observed between case and control groups (p< 0.001). We noted that 47.1 percent of the patients and 17.96% of the controls had a lipoprotein (a) level more than 30 mg/dl which is a critical level for coronary artery disease. There was no significant difference in other lipid parameters between two groups. The family history of androgenic alopecia and coronary heart disease was significantly higher in the cases than the controls.Conclusion: Considering the results of the study and the important role of lipoprotein (a) as a risk factor for atherosclerotic heart disease, we suggest that all men with a male pattern hair loss should be investigated for lipid indices, especially lipoprotein (a).
Farajzadeh Saeedeh; Esfandiarpour Iraj; Abbassi Mohammad Mehdi Hayatbatch; Moghaddam Sodaif Darvish; Hosseininasab Fatemeh
Volume 13, Issue 3 , 2010, , Pages 78-81
Abstract
Background: The correlation between coronary artery disease and androgenic alopecia has been demonstrated, but the mechanism of this association still remains to be cleared. Objective: To investigate lipid profile, as an indicator of coronary artery disease, in women with female pattern alopecia. Methods: ...
Read More
Background: The correlation between coronary artery disease and androgenic alopecia has been demonstrated, but the mechanism of this association still remains to be cleared. Objective: To investigate lipid profile, as an indicator of coronary artery disease, in women with female pattern alopecia. Methods: Fifty one women with female pattern alopecia and thirty one healthy women with normal hair status were selected as the case and control groups, respectively. Lipid profile including cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, lipoprotein (a), apolipoprotein A1, and apolipoprotein B were measured in both groups. Results: The most important result of our study was a remarkably higher level of lipoprotein (a) in the case group. On the other hand, 55.3% of the patients and 16.7 % of the controls had lipoprotein (a) level >30 mg/dl, higher than the critical level for atherosclerosis. Conclusion: Lipid profile, especially lipoprotein (a), which is an important risk factor for coronary artery disease, should be investigated in women with androgenic alopecia. Those with disturbance in lipid profile should be referred to a cardiologist.
N Bouzari; AR Firooz; H Tabatabai; Y Dowlati
Volume 4, Issue 3 , 2001, , Pages 24-29
Abstract
Background: Minoxidil is currently an approved treatment for androgenetic alopecia. Topical tretinoin can enhance skin absorption of minoxidil. Objective: This study has been done in order to determine the efficacy and safety of the solution of 0.5% minoxidil+0.05% tretinoin compared to 2% minoxidil ...
Read More
Background: Minoxidil is currently an approved treatment for androgenetic alopecia. Topical tretinoin can enhance skin absorption of minoxidil. Objective: This study has been done in order to determine the efficacy and safety of the solution of 0.5% minoxidil+0.05% tretinoin compared to 2% minoxidil in androgenetic alopecia in men. Patients and Methods: In a randomized, double-blind, parallel-group, controlled study, 117 male patients with androgenetic alopecia, 18-40 years old, Hamilton grades of 2-5 and duration of alopecia less than 10 years were evaluated. These patients were divided in two groups randomly, one group received a solution containing 0.5% minoxidil and 0.05% tretinoin and another group received 2% minoxidil for at least 4 months. The patients used 1ml of the solution twice daily. 2 and 4 months after treatment, the patients were evaluated for efficacy (Patients, idea about improvement of hair loss, hair regrowth and wash test) and safety (Erythema, scaling and pruritus). The quantitative data were analyzed by ANOVA and the qualitative data were analyzed by qui-squared test. Results: There were no significant differences between two groups regarding the age, duration and grade of hair loss. After 4 months of treatment, the percentage of patients reporting improvement in hair loss and hair regrowth were 81.6% and 56% in minoxidil 2% group and 65.4% and 59.6% in minoxidil+tretinoin group, respectively (P>0.05 for all). At the same time, the numbers of hairs in wash test were 156 in minoxidil 2% group and 149 in minoxidil+tretinoin group (P>0.05). Conclusion: There was no significant difference in efficacy and safety of 4 months treatment with the solution of 0.5% minoxidil and 0.05% tretinoin compared to the solution of 2% minoxidil in the treatment of androgenetic alopecia in men.